Actelion shares plunge as Tracleer fails to meet primary endpoint in idiopathic pulmonary fibrosis

2 March 2010

Switzerland's Actelion yesterday saw its shares plunge 16.2% to 45.90 Swiss francs, its lowest level for four years, after the company announced the initial results of BUILD-3, a clinical study evaluating the safety and efficacy of its lead product bosentan (sold as Tracleer) in patients suffering from idiopathic pulmonary fibrosis (IPF). While there was a consistent trend in favor of bosentan, the primary endpoint, reduction in morbidity/mortality, was not met (p=0.21). However, the company noted, the well characterized safety profile of bosentan was confirmed.

Jean-Paul Clozel, chief executive of Actelion, Europe's largest biotechnology company, commented: "We are naturally disappointed with this outcome. While in BUILD-3 there is a consistent trend in favor of bosentan, these findings do not support initiating regulatory proceedings."

Notwithstanding, a company spokesman stated that the news does not change the Actelion's financial targets for 2010 for sales growth of more than 10% and cash earnings before interest and taxes rising nearly 20%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology